Functionalized nanoparticles for brain targeted BDNF gene therapy to rescue Alzheimer's disease pathology in transgenic mouse model
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Brain-derived neurotrophic factor (BDNF) is actively produced and utilized in cortical circuits throughout life to sustain neuronal function and synaptic plasticity. In animal models of Alzheimer's Disease (AD), highly invasive BDNF gene therapy using viral vectors has successfully shown enhanced synaptic protein expression, proliferation of neurons and attenuation of amyloidogenic processes. However, to eliminate virus-related safety issues and invasive procedures, our present study has explored brain-targeted lipid-based nanoparticles that can deliver plasmid encoding BDNF to brain in a safe and efficient manner. Efficacy of these nanoparticles was tested in early (6-months) and advanced stage (9-months) transgenic APP/PS1 AD mice. Liposomes were surface-functionalized with brain targeting ligand, mannose, and cell-penetrating peptides (rabies virus-derived peptide or penetratin). These bifunctionalized nanoparticles enhanced BDNF expression by ~2 times and resulted in >40% (p < 0.05) reduction in toxic amyloid-beta peptides in 6- and 9-months old APP/PS1 mice brains compared to their age-matched untreated controls. Plaque load was reduced ~7 and ~3 times (p < 0.05), respectively, whereas synaptic proteins, synaptophysin and PSD-95, were found to be increased >90% (p < 0.05) in both age groups of transgenic mice treated with bifunctionalized nanoparticles. No untoward adverse effects were observed throughout treatment, suggesting a safe and effective strategy to rescue AD pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BDNF: A Key Factor with Multipotent Impact on Brain Signaling and Synaptic Plasticity
Kowiański, P., Lietzau, G., Czuba, E., Waśkow, M., Steliga, A., & Moryś, J. (2018) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0510-4 · Cited by 1,359
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034
Brain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
Potential therapeutic uses of BDNF in neurological and psychiatric disorders
Nagahara, A. H., & Tuszynski, M. H. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3366 · Cited by 867
Peng, S., Wuu, J., Mufson, E. J., & Fahnestock, M. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03135.x · Cited by 691
Protein synthesis and neurotrophin-dependent structural plasticity of single dendritic spines
Tanaka, J.-I., Horiike, Y., Matsuzaki, M., Miyazaki, T., Ellis-Davies, G. C. R., & Kasai, H. (2008) · Science · doi:10.1126/science.1152864 · Cited by 615
NGF and BDNF signaling control amyloidogenic route and Aβ production in hippocampal neurons
Matrone, C., Ciotti, M. T., Mercanti, D., Marolda, R., & Calissano, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806133105 · Cited by 169
Arora, S., Layek, B., & Singh, J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00461 · Cited by 149
Self-citationFilali, M., & Lalonde, R. (2009) · Brain Research · doi:10.1016/j.brainres.2009.07.066 · Cited by 121
Cited by
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
Kamatham, P. T., Shukla, R., Khatri, D. K., & Vora, L. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102481 · Cited by 371
Muolokwu, C. E., Chaulagain, B., Gothwal, A., Mahanta, A. K., Tagoe, B., Lamsal, B., & Singh, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1405423 · Cited by 42
Self-citationAdvances in nanotechnology for targeted drug delivery in neurodegenerative diseases
Rafieezadeh, D. (2025) · American Journal of Neurodegenerative Disease · doi:10.62347/qhvi3317 · Cited by 20
Liu, H.-J., Wang, M., Wang, Y., Shi, S., Hu, X., Zhang, D.-B., Fan, D., Mintzer, J., & Xu, P. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100158 · Cited by 13
Metadata
- Authors
- Arora, S., Kanekiyo, T., & Singh, J.
- Venue
- International Journal of Biological Macromolecules
- Publisher
- Elsevier BV
- Published
- 2022-05
- Volume
- 208
- Pages
- 901-911
- ISSN
- 0141-8130 (ISSN-L)
- OpenAlex
- W4223437978
- Cited by
- 67
- References
- 13
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Functionalized nanoparticles for brain targeted BDNF gene therapy to rescue Alzheimer's disease pathology in transgenic mouse model. https://app.cochat.ai/papers/10.1016/j.ijbiomac.2022.03.203
- The paper
- Arora, S., Kanekiyo, T., & Singh, J. (2022). Functionalized nanoparticles for brain targeted BDNF gene therapy to rescue Alzheimer's disease pathology in transgenic mouse model. International Journal of Biological Macromolecules. https://doi.org/10.1016/j.ijbiomac.2022.03.203
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.